ME01648B - Kombinacija inhibitora hmg-coa reduktaze rosuvastatina sa inhibitorom fosfodiesteraze 4,kao što je roflumilast, roflumilast-n-oksid za liječenje inflamatornih plućnih oboljenja - Google Patents

Kombinacija inhibitora hmg-coa reduktaze rosuvastatina sa inhibitorom fosfodiesteraze 4,kao što je roflumilast, roflumilast-n-oksid za liječenje inflamatornih plućnih oboljenja

Info

Publication number
ME01648B
ME01648B MEP-2014-9A MEP914A ME01648B ME 01648 B ME01648 B ME 01648B ME P914 A MEP914 A ME P914A ME 01648 B ME01648 B ME 01648B
Authority
ME
Montenegro
Prior art keywords
roflumilast
hmg
coa reductase
pharmaceutically acceptable
inhibitor
Prior art date
Application number
MEP-2014-9A
Other languages
English (en)
French (fr)
Inventor
Stefan-Lutz Wollin
Degenhard Marx
Andrea Wohlsen
Clemens Braun
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of ME01648B publication Critical patent/ME01648B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (34)

1.Farmaceutska kompozicija koja sadrži farmaceutsku formulaciju koja uključuje količinu PDE4 inhibitora, količinu inhibitora HMG-CoA reduktaze i bar jednu farmaceutsku prihvatljivu pomoćnu supstancu, gde je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILASTA, farmaceutske prihvatljive soli ROFLUMILASTA, ROFLUMILAST-N-oksida i farmaceutske prihvatljive soli ROFLUMILAST-N-oksida, inhibitor HMG-CoA reduktaze je ROSUVASTATIN ili njegova farmaceutski prihvatljiva so, gde prva količina i druga količina zajedno obuhvataju efikasnu količinu za preventivni ili lekoviti tretman inflamatornog plućnog obolenja.
2.Kombinovani proizvod koji sadrži komponente: (A) količinu PDE4 inhibitora; (B) količinu inhibitora HMG-CoA reduktaze; pri čemu prva i druga količina zajedno obuhvataju efikasnu količinu za preventivno ili lekovito lečenje inflamatornog plućnog obolenja, pri čemu je svaka od komponenti (A) i (B) formulisana u smeši sa bar jednom farmaceutskom prihvatljivom pomoćnom supstancom, i gde je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILASTA, farmaceutski prihvatljive soli ROFLUMILASTA, ROFLUMILAST-N-oksida i farmaceutske prihvatljive soli ROFLUMILAST-N-oksida, a inhibitor HMG-CoA reduktaze je ROSUVASTATIN ili njegova farmaceutski prihvatljiva so.
3.Oprema koja sadrži komponente: (A) farmaceutsku formulaciju koja obuhvata količinu PDE4 inhibitora, u smeši sa bar jednom farmaceutski prihvatljivom pomoćnom supstancom; (B) farmaceutsku formulaciju koja obuhvata količinu inhibitora HMG-CoA reduktaze, u smeši sa bar jednom farmaceutski prihvatljivom pomoćnom supstancom; gde prva i druga količina zajedno obuhvataju efikasnu količinu za preventivno ili lekovito lečenje inflamatornog plućnog obolenja, i gde je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILASTA, farmaceutski prihvatljive soli ROFLUMILASTA, ROFLUMILAST-N-oksida i farmaceutske prihvatljive soli ROFLUMILAST-N-oksida, a inhibitor HMG-CoA reduktaze je ROSUVASTATIN ili njegova farmaceutski prihvatljiva so.
4.Farmaceutska kompozicija prema zahtevu 1, gde PDE 4 inhibitor je ROFLUMILAST.
5.Farmaceutska kompozicija prema zahtevu 1, gde PDE4 inhibitor je ROFLUMILAST- N- oksid.
6.Farmaceutska kompozicija prema bilo kom od zahteva 1, 4 ili 5, gde inhibitor HMG-CoA reduktazeje ROSUVASTATIN hemi-kalcijum.
7.Farmaceutska kompozicija prema bilo kom od zahteva 1, 4 ili 5, gde inhibitor HMG-CoA reduktazeje ROSUVASTATIN natrijum.
8.Farmaceutska kompozicija prema bilo kom od zahteva 1, 4 ili 5, gde inhibitor HMG-CoA reduktaze je ROSUVASTATIN.
9. Kombinovani proizvod prema zahtevu 2, gde PDE4 inhibitor je ROFLUMILAST.
10. Kombinovani proizvod prema zahtevu 2, gde PDE4 inhibitor je ROFLUMILAST-N-oksid.
11.Kombinovani proizvod prema bilo kom od zahteva 2, 9 ili 10, gde inhibitor HMG-CoA reduktazeje ROSUVASTATIN hemi-kalcijum.
12.Kombinovani proizvod prema bilo kom od zahteva 2, 9 ili 10, gde inhibitor HMG-CoA reduktazeje ROSUVASTATIN natrijum.
13.Kombinovani proizvod prema bilo kom od zahteva 2, 9 ili 10, gde inhibitor HMG-CoA reduktazeje ROSUVASTATIN.
14.Oprema prema zahtevu 3, gde PDE4 inhibitor je Roflumilast.
15.Oprema prema zahtevu 3, gde PDE4 inhibitor je ROFLUMILAST-N-oksid.
16.Oprema prema bilo kom od zahteva 3, 14 ili 15, gde inhibitor HMG-CoA reduktaze je ROSUVASTATIN hemi-kalcijum.
17.Oprema prema bilo kom od zahteva 3, 14 ili 15, gde inhibitor HMG-CoA reduktaze je ROSUVASTATIN natrijum.
18.Oprema prema bilo kom od zahteva 3, 14 ili 15, gde inhibitor HMG-CoA reduktaze je ROSUVASTATIN.
19.Farmaceutska kompozicija prema bilo kom od zahteva 1, 4, 5, 6, 7 ili 8, gde je inflamatorno plućno obolenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
20.Farmaceutska kompozicija prema bilo kom od zahteva 1, 4, 5, 6, 7 ili 8, pri čemu je inflamatorno plućno obolenje COPD.
21.Kombinovani proizvod prema bilo kom od zahteva 2, 9, 10, 11, 12 ili 13, gde je inflamatorno plućno obolenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
22.Kombinovani proizvod prema bilo kom od zahteva 2, 9, 10, 11, 12 ili 13, gde je inflamatorno plućno obolenje COPD.
23.Oprema prema bilo kom od zahteva 3, 14, 15, 16, 17 ili 18, gde je inflamatorno plućno obolenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
24.Oprema prema bilo kom od zahteva 3, 14, 15, 16, 17 ili 18, gde je inflamatorno plućno obolenje COPD.
25.Primena PDE4 inhibitora i inhibitora HMG-CoA reduktaze za proizvodnju medikamenta, prvenstveno farmaceutske kompozicije prema pronalasku, za preventivnu ili lekovitu terapiju inflamatornog plućnog obolenja, pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILASTA, farmaceutski prihvatljive soli ROFLUMILASTA, ROFLUMILAST-N- oksida i farmaceutske prihvatljive soli ROFLUMILAST-N-oksida, a inhibitor HMG-CoA reduktaze je ROSUVASTATIN ili njegova farmaceutski prihvatljiva so.
26.Primena PDE4 inhibitora i inhibitora HMG-CoA reduktaze za proizvodnju uzastopnog ili odvojenog medikamenta za istovremenu primenu, prvenstveno kombinovanog proizvoda ili opreme prema pronalasku, za preventivnu ili lekovitu terapiju inflamatornog plućnog obolenja, pri čemu je PDE4 inhibitor odabran iz grupe koja se sastoji od ROFLUMILASTA, farmaceutski prihvatljive soli ROFLUMILASTA, ROFLUMILAST-N-oksida i farmaceutske prihvatljive soli ROFLUMILAST-N-oksida, a inhibitor HMG-CoA reduktaze je ROSUVASTATIN ili njegova farmaceutski prihvatljiva so.
27.Primena prema bilo kom od zahteva 25 ili 26, gde PDE4 inhibitor je ROFLUMILAST.
28.Primena prema bilo kom od zahteva 25 ili 26, gde PDE4 inhibitor je ROFLUMILAST-N- oksid.
29.Primena prema bilo kom od zahteva 25, 26, 27 ili 28, gde inhibitor HMG-CoA reduktaze je ROSUVASTATIN hemi-kalcijum.
30.Primena prema bilo kom od zahteva 25, 26, 27 ili 28, gde inhibitor HMG-CoA reduktaze je ROSUVASTATIN natrijum.
31.Primena prema bilo kom od zahteva 25, 26, 27 ili 28, gde inhibitor HMG-CoA reduktaze je ROSUVASTATIN.
32.Primena prema bilo kom od zahteva 25 do 31, gde je inflamatorno plućno obolenje odabrano iz grupe koja se sastoji od astme, COPD, skleroze, alveolitisa, sarkoidoze, idiopatične pulmonarne fibroze i pulmonarne hipertenzije.
33.Primena prema bilo kom od zahteva 25 do 31, gde je inflamatorno plućno obolenje COPD.
34.Postupak za pripremanje farmaceutske kompozicije kao što je definisano u bilo kom od zahteva 1, 4, 5, 6, 7, 8, 19 ili 20, koji obuhvata mešanje PDE4 inhibitora ili njegove farmaceutski prihvatljive soli sa inhibitorom HMG-CoA reduktaze ili njegovom farmaceutski prihvatljivom soli.
MEP-2014-9A 2006-07-05 2007-07-03 Kombinacija inhibitora hmg-coa reduktaze rosuvastatina sa inhibitorom fosfodiesteraze 4,kao što je roflumilast, roflumilast-n-oksid za liječenje inflamatornih plućnih oboljenja ME01648B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06116625 2006-07-05
PCT/EP2007/056683 WO2008003701A2 (en) 2006-07-05 2007-07-03 Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
EP11164516.4A EP2359826B1 (en) 2006-07-05 2007-07-03 Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases

Publications (1)

Publication Number Publication Date
ME01648B true ME01648B (me) 2014-09-20

Family

ID=37311957

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2014-9A ME01648B (me) 2006-07-05 2007-07-03 Kombinacija inhibitora hmg-coa reduktaze rosuvastatina sa inhibitorom fosfodiesteraze 4,kao što je roflumilast, roflumilast-n-oksid za liječenje inflamatornih plućnih oboljenja
MEP-2014-91A ME01901B (me) 2006-07-05 2007-07-03 Kombinacija inhibitora HMG-CoA reduktaze atorvastatina ili simvastatina sa fosfodiesteraza 4 inhibitorom, kao što je roflumilast za lečenje inflamatornih pulmonarnih oboljenja

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2014-91A ME01901B (me) 2006-07-05 2007-07-03 Kombinacija inhibitora HMG-CoA reduktaze atorvastatina ili simvastatina sa fosfodiesteraza 4 inhibitorom, kao što je roflumilast za lečenje inflamatornih pulmonarnih oboljenja

Country Status (26)

Country Link
US (2) US20100069392A1 (me)
EP (3) EP2359826B1 (me)
JP (3) JP5349302B2 (me)
KR (1) KR101433394B1 (me)
CN (3) CN101484166B (me)
AT (1) ATE535244T1 (me)
AU (1) AU2007271186C1 (me)
BR (1) BRPI0713768A2 (me)
CA (1) CA2656366A1 (me)
CY (2) CY1114742T1 (me)
DK (2) DK2359826T3 (me)
EA (2) EA021461B1 (me)
ES (3) ES2378281T3 (me)
HR (2) HRP20140073T1 (me)
IL (3) IL195433A (me)
ME (2) ME01648B (me)
MX (1) MX2008016123A (me)
NO (1) NO342590B1 (me)
NZ (3) NZ603207A (me)
PL (2) PL2359826T3 (me)
PT (2) PT2363130E (me)
RS (2) RS53461B (me)
SI (2) SI2359826T1 (me)
UA (3) UA98466C2 (me)
WO (1) WO2008003701A2 (me)
ZA (1) ZA200809905B (me)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513203A (ja) * 2008-03-14 2011-04-28 大塚製薬株式会社 Ｍｍｐ−２及び／又はｍｍｐ−９阻害剤
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法
WO2015185658A2 (en) 2014-06-05 2015-12-10 Medizinische Universität Wien Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers
WO2015185656A1 (en) * 2014-06-05 2015-12-10 Medizinische Universität Wien Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers
JP6755240B2 (ja) * 2014-06-05 2020-09-16 トランスゲニオン−インターナショナル インスティテュート フォー リジェネレイティヴ トランスレイショナル メディシン ゲーエムベーハー 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法
US12582809B2 (en) 2018-01-26 2026-03-24 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2021218988A1 (zh) * 2020-04-30 2021-11-04 中国科学院上海药物研究所 Prdx1激动剂及其用途
US20240042147A1 (en) * 2022-08-03 2024-02-08 Chiesi Farmaceutici S.P.A. Dry powder inhaler

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR69216B (me) 1979-06-15 1982-05-07 Merck & Co Inc
AU548996B2 (en) 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
WO1984002131A1 (fr) 1982-11-22 1984-06-07 Sandoz Ag Produits analogues de mevalolactone et leurs derives, leurs procedes de production, compositions pharmaceutiques les contenant ainsi que leur utilisation en tant que produits pharmaceutiques
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
EP0307342B1 (de) 1987-07-10 1996-01-03 Hoechst Aktiengesellschaft 3-Desmethyl-mevalonsäurederivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate auf Basis dieser Verbindungen, ihre Verwendung sowie Zwischenprodukte
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US4863957A (en) 1987-12-21 1989-09-05 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
FR2642065B1 (fr) 1989-01-24 1991-05-24 Lipha Derives d'acides benzocycloalcenyl dihydroxy alcanoiques, procede de preparation et medicaments les contenant
CA2074933C (en) 1990-11-30 2002-12-03 Masatoshi Chihiro Thiazole derivatives as active superoxide radical inhibitors
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU225869B1 (en) 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
EP0919544B1 (en) * 1992-04-02 2003-05-14 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
DE59410119D1 (de) * 1993-07-02 2002-06-20 Byk Gulden Lomberg Chem Fab Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
GB9504460D0 (en) 1995-03-06 1995-04-26 Bayer Ag N-(3-Benzofuranyl)urea-derivatives
DE69525978T2 (de) 1995-06-06 2002-12-19 Pfizer Trizyclische 5,6-dihydro-9h-pyrazolo(3,4-c)-1,2,4-triazolo(4,3-alpha)pyridine
DE19636150A1 (de) 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
DE59913617D1 (de) 1998-04-28 2006-08-03 Elbion Ag Indolderivate und deren Verwendung als Inhibitoren der Phosphodiesterase 4.
US20010006656A1 (en) 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
DE19944161A1 (de) 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
MY134008A (en) 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
EP1275388A4 (en) 2000-02-10 2003-11-26 Takeda Chemical Industries Ltd Tnf- alpha inhibitors
JP2001294526A (ja) * 2000-02-10 2001-10-23 Takeda Chem Ind Ltd ＴＮＦ−α抑制剤
MY123585A (en) 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
US20050102317A1 (en) * 2000-07-21 2005-05-12 Ali Kamarei System and method for event calendaring using a customizable rules subset
WO2002024194A2 (en) 2000-09-19 2002-03-28 Novimmune S.A. Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US6740666B2 (en) * 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
HRP20030636B1 (en) * 2001-02-15 2012-05-31 Nycomed Gmbh Phthalayinone-piperidino-derivatives as pde4 inhibitors
IL157734A0 (en) * 2001-03-06 2004-03-28 Cellegy Pharma Inc Pharmaceutical compositions for the treatment of urogenital disorders
JP4193435B2 (ja) * 2002-07-23 2008-12-10 ブラザー工業株式会社 インクカートリッジ、および、そのインク充填方法
EP1397359B1 (en) * 2001-05-24 2005-08-31 Merck Frosst Canada & Co. 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
ATE296630T1 (de) * 2001-06-27 2005-06-15 Merck Frosst Canada Inc Substituierte 8-arylchinoline als pde4-hemmer
US20030114469A1 (en) 2001-09-27 2003-06-19 Cohen David Saul Combinations
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
WO2004005258A1 (en) * 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors
AU2003294312A1 (en) * 2002-11-18 2004-07-09 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
IS7839A (is) 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
BR0316451A (pt) * 2002-11-27 2005-10-11 Altana Pharma Ag Combinação sinergìstica compreendendo roflumilast e formoterol
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
WO2004091626A1 (en) * 2003-04-07 2004-10-28 Osteoscreen, Inc. Bone growth stimulation with no/statin and other no modulating combinations
WO2004089940A1 (en) 2003-04-11 2004-10-21 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
JP2006524638A (ja) * 2003-04-30 2006-11-02 メルク フロスト カナダ リミテツド ８−（３−ビアリール）フェニルキノリン系ホスホジエステラーゼ−４阻害薬
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
WO2004103407A2 (en) * 2003-05-22 2004-12-02 Altana Pharma Ag Composition comprising a pde4 inhibitor and a pde5 inhibitor
WO2005000217A2 (en) * 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
US20060160834A1 (en) * 2003-06-06 2006-07-20 Fong Tung M Combination therapy for the treatment of hypertension
DE10348646A1 (de) 2003-10-15 2005-05-25 Gkn Driveline International Gmbh Rollbalg mit großem Krümmungsradius
WO2005102348A1 (en) * 2004-04-19 2005-11-03 Loma Linda University Composition and method of decreasing renal ischemic damage
WO2005102317A1 (en) * 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0415789D0 (en) * 2004-07-15 2004-08-18 Astrazeneca Ab Novel combination
DE102004046236A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
GB0508924D0 (en) 2005-04-30 2005-06-08 Astrazeneca Ab New use
GB0510207D0 (en) 2005-05-19 2005-06-22 Astrazeneca Ab Novel combination
PL1894576T3 (pl) 2005-06-08 2011-10-31 Kowa Co Nowy środek do obniżania poziomu triglicerydów
US7985756B2 (en) * 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
AR057555A1 (es) * 2005-10-27 2007-12-05 Merck Frosst Canada Ltd Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
SG166829A1 (en) 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US20080103105A1 (en) * 2006-09-22 2008-05-01 Braincells, Inc. HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS

Also Published As

Publication number Publication date
JP2009541459A (ja) 2009-11-26
WO2008003701A2 (en) 2008-01-10
JP5349302B2 (ja) 2013-11-20
AU2007271186A1 (en) 2008-01-10
PT2359826E (pt) 2014-01-20
HRP20140707T1 (hr) 2014-09-12
NZ594369A (en) 2013-10-25
BRPI0713768A2 (pt) 2012-10-30
US20150272949A1 (en) 2015-10-01
ME01901B (me) 2014-12-20
IL221307A0 (en) 2012-09-24
CN102764440A (zh) 2012-11-07
CN102772411A (zh) 2012-11-14
KR101433394B1 (ko) 2014-08-26
CN101484166B (zh) 2012-09-05
EA032476B1 (ru) 2019-06-28
ATE535244T1 (de) 2011-12-15
ES2378281T3 (es) 2012-04-10
SI2363130T1 (sl) 2014-09-30
PL2363130T3 (pl) 2014-09-30
IL221307A (en) 2014-08-31
ES2443342T3 (es) 2014-02-19
IL195433A0 (en) 2009-08-03
IL195433A (en) 2013-02-28
EP2040707B1 (en) 2011-11-30
HRP20140073T1 (hr) 2014-02-28
ZA200809905B (en) 2009-11-25
ES2489265T3 (es) 2014-09-01
PL2359826T3 (pl) 2014-04-30
MX2008016123A (es) 2009-01-15
SI2359826T1 (sl) 2014-02-28
DK2359826T3 (da) 2014-01-20
CA2656366A1 (en) 2008-01-10
AU2007271186C1 (en) 2013-08-15
CN101484166A (zh) 2009-07-15
UA106422C2 (uk) 2014-08-26
NZ603207A (en) 2013-12-20
EP2359826B1 (en) 2013-10-30
RS53461B (sr) 2014-12-31
RS53084B (sr) 2014-06-30
NO342590B1 (no) 2018-06-18
PT2363130E (pt) 2014-06-25
DK2363130T3 (da) 2014-07-21
EP2040707A2 (en) 2009-04-01
EA200900073A1 (ru) 2009-06-30
JP2013035870A (ja) 2013-02-21
EP2363130B1 (en) 2014-05-07
EP2359826A1 (en) 2011-08-24
JP2013035871A (ja) 2013-02-21
NO20090370L (no) 2009-02-04
EP2363130A1 (en) 2011-09-07
AU2007271186B2 (en) 2013-01-17
UA98466C2 (uk) 2012-05-25
CY1114742T1 (el) 2016-12-14
KR20090025368A (ko) 2009-03-10
NZ573378A (en) 2012-03-30
UA101556C2 (uk) 2013-04-10
WO2008003701A3 (en) 2008-03-13
EA021461B1 (ru) 2015-06-30
IL221309A (en) 2014-12-31
CY1115462T1 (el) 2017-01-04
US20100069392A1 (en) 2010-03-18
US9713614B2 (en) 2017-07-25
EA201401042A1 (ru) 2016-05-31

Similar Documents

Publication Publication Date Title
HRP20140073T1 (hr) Kombinacija rosuvastatina inhibitora reduktaze hmg-coa s inhibitorom fosfodiesteraze-4, kao što je roflumilast, roflumilast-n-oksid, za lijeäśenje pluä†nih bolesti
HRP20170624T1 (hr) Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti
BRPI0616694B8 (pt) processo para preparar comprimido farmacêutico com 80 e 96% em peso com base no peso seco de vildagliptina e metformina ou seus sais farmaceuticamente aceitáveis
MX364937B (es) Composiciones farmaceuticas de acido 3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico y su administracion.
NZ600790A (en) Combination therapy for copd
MX2010001338A (es) Derivados de pirimidina y piridina y su uso y composiciones farmaceuticas.
HRP20251173T1 (hr) Triciklički parp1 inhibitori i njihove uporabe
EA200500096A1 (ru) Гетеробиарильные производные в качестве ингибиторов матриксных металлопротеиназ
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
WO2008074834A3 (en) Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase (scd)
TW200806300A (en) New therapeutic combinations for the treatment of depression
WO2008074832A3 (en) Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase ( scd)
AR078951A1 (es) Esferoides de farmacos revestidos y usos de los mismos para la eliminacion o reduccion de afecciones tales como emesis y diarrea
CY1112702T1 (el) Βελτιωμενη φαρμακευτικη συνθεση που περιεχει εναν αντισπασμωδικο παραγοντα πυρρολιδονης και μεθοδος για την παρασκευη της
WO2008074833A3 (en) Compounds
PH12018502521A1 (en) Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
BRPI0509720A (pt) derivados de 4-alquil- e 4-alcanoil-piperidina substituìda e seu uso como antagonistas de neurocinina
HRP20110023T1 (hr) Smanjenje prekomjerne težine ili pretilosti
WO2007111983A3 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
MX2025010948A (es) Derivados fusionados con tiofeno sustituido, composiciones que los comprenden y su uso como productos farmacéuticos
WO2009049648A3 (en) Improved pharmaceutical composition containing antiviral agent and method for the preparation thereof
BRPI0608074A2 (pt) derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo
CA2633077A1 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof